Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response
Hannah L. Chang, Blake Schwettmann, Heather L. McArthur, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 18
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance
Meiting Chen, Riqing Huang, R.C. Chen, et al.
The Oncologist (2024) Vol. 29, Iss. 8, pp. e957-e966
Open Access | Times Cited: 10
Research progress in tumor angiogenesis and drug resistance in breast cancer
Jiancheng Mou, Chenhong Li, Qinghui Zheng, et al.
Cancer Biology and Medicine (2024), pp. 1-15
Open Access | Times Cited: 8
EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells
Bita Jafary, Mostafa Akbarzadeh-Khiavi, Hamed Farzi-Khajeh, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Bispecific Aptamer-Drug Conjugates Selectively Eliminate Malignant Hematologic Cells for Treating Acute Myeloid Leukemia
Xiaodong Li, Jiacheng Dai, Yuanyuan Shi, et al.
Langmuir (2025)
Closed Access
Efferocytosis-related gene IL33 predicts prognosis and immune response and mediates proliferation and migration in vitro and in vivo of breast cancer
He Xiao, Xi Cheng, Zhun Zhang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Silver Jubilee of HER2 targeting: a clinical success in breast cancer
Jianli Zhao, Ziyue Zhou, Phei Er Saw, et al.
Journal of the National Cancer Center (2025)
Open Access
Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer
Khalil Saleh, Rita Khoury, Nadine Khalife, et al.
Cancer Drug Resistance (2024)
Open Access | Times Cited: 4
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer
Giuseppe Saltalamacchia, Rosalba Torrisi, Rita De Sanctis, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 500-500
Open Access | Times Cited: 3
Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance
Samuele Tardito, Serena Matis, Maria Raffaella Zocchi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7131-7131
Open Access | Times Cited: 3
Antibody drug conjugates in the clinic
Edidiong Udofa, Disha Sankholkar, Samir Mitragotri, et al.
Bioengineering & Translational Medicine (2024) Vol. 9, Iss. 6
Open Access | Times Cited: 2
Tuning Immune‐Cold Tumor by Suppressing USP10/B7‐H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs
Lidan Zeng, Yueming Zhu, Xin Cui, et al.
Advanced Science (2024) Vol. 11, Iss. 40
Open Access | Times Cited: 2
Present and Future of Immunotherapy for Triple-Negative Breast Cancer
Sushmitha Sriramulu, Shivani Thoidingjam, Corey Speers, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3250-3250
Open Access | Times Cited: 2
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
Alvan Cai, Yuan Chen, Lily S. Wang, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2635-2635
Open Access | Times Cited: 1
Exploring bacterial key genes and therapeutic agents for breast cancer among the Ghanaian female population: Insights from In Silico analyses
Md. Kaderi Kibria, Md. Ahad Ali, Md. Nurul Haque Mollah
PLoS ONE (2024) Vol. 19, Iss. 11, pp. e0312493-e0312493
Open Access | Times Cited: 1
Antibody drug conjugates in breast cancer in China: Highlights, challenges, and prospects
Jianbin Li, Zefei Jiang
Cancer (2023) Vol. 130, Iss. S8, pp. 1371-1377
Closed Access | Times Cited: 3
Design, synthesis and bioactivity evaluation of novel monomethyl auristatin F analogues
Lisheng Yang, Xinglin Li, Lei Zhao, et al.
Research Square (Research Square) (2024)
Open Access
Cyclosporin A Enhance the Cytotoxicity of Immunotoxin to the HER-2-Overexpressing SK-OV-3 Cells: A Prospective Study
huilong xie, Yunrong Fu, Zhisheng Lin, et al.
Revista Brasileira de Farmacognosia (2024) Vol. 34, Iss. 5, pp. 1059-1070
Closed Access
Design, synthesis and bioactivity evaluation of novel monomethyl auristatin F analogues
Lisheng Yang, Xinglin Li, Lei Zhao, et al.
Molecular Diversity (2024)
Closed Access
Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer
Sho Sato, Tadahiro Shoji, Ami Jo, et al.
Cancers (2024) Vol. 16, Iss. 14, pp. 2545-2545
Open Access
Impact of neoadjuvant chemotherapy on perioperative immune function in breast cancer patients: a propensity score-matched retrospective study
Qihua Jiang, Hai Hu, Zhihong Xu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Comparative Analysis and Future Prospects of Human Epidermal Growth Factor Receptor 2 (HER2) and Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted Antibody-Drug Conjugates in Breast Cancer Treatment
Xiaojuan Gao, Tiansheng Bu, Wenying Wang, et al.
Breast Cancer Targets and Therapy (2024) Vol. Volume 16, pp. 621-630
Open Access
Dual immunostimulatory CD73 antibody-polymeric cytotoxic drug complex for triple negative breast cancer therapy
Xiao Hua Xie, Ming Yang, Wei Xue, et al.
Acta Biomaterialia (2024) Vol. 189, pp. 532-544
Closed Access
Mechanisms of resistance of antibody-drug conjugates—Obstacles to overcome
Yanitsa Davidkova, Milan Jagurinoski, Margarita Guenova
Elsevier eBooks (2024), pp. 257-273
Closed Access
Zinc finger protein 593 promotes breast cancer development by ensuring DNA damage repair and cell cycle progression
Yingfan Zhang, Xiaowen Tang, Chenxin Wang, et al.
iScience (2024) Vol. 27, Iss. 12, pp. 111513-111513
Closed Access
Mining and analysis of adverse event signals of trastuzumab deruxtecan via real-world data of FDA adverse event reporting system database from 2019 to 2023
Xiangyu Li, Fang Yang, Fuqun Zhou, et al.
Expert Opinion on Drug Safety (2024), pp. 1-10
Closed Access
Page 1 - Next Page

Scroll to top